Scientists pioneer new drug regimen that reduces toxicities for renal cancer patients

Conclusive results have been revealed in reducing toxicities for Asian patients with metastatic renal cell carcinoma or cancer that has spread beyond the kidney. The findings have revolutionized the standard protocol for patient management in NCCS with an attenuated-dose regimen of sunitinib for patients with mRCC. (Mehr in: Cancer News — ScienceDaily)